INTRODUCTION
The Pharmaceutical Industry has a vital role within the world economy, as well as ensuring the welfare of humans worldwide. The pharmaceutical industry develops, produces and markets drugs licensed for use as medication, which could be generic and or brand medication. The pharmaceutical industry is subject to a verity of laws and regulations regarding patenting, testing and marketing drugs. In today's society, drugs are major source of relief for many illnesses. According to the World Health Organization (WHO), one-third of the world population cannot access medicines they need. An important reason for this is that prices are often too high for people or government-funded health systems to afford. In developing countries, most people who need medical drugs have to pay for them out of their own pockets. Where the cost of drugs is covered by health systems, spending on medicines is a major part of the total healthcare budget (1) .
Two major forms of drugs are sold, patented drugs that are protected either through product or process patent and known by their trade name, and a generic medicine that means a prescription medicine based on an active substance that is out of patent and marketed under a different name from that of the original branded medicine (2) . The generic medicine manufacturers play an important role in offering affordable medicines to patients after the expiry of the patent protection period as generic drugs are seen predominantly as a low-cost alternative to patented drugs (3) .
Jordan is classified as a lower-middle income country in which the largest provider of health care is the public sector via the Ministry of Health (MOH), providing insurance to 40% of the population, followed by the Royal Medical Services (RMS), covering 27.5% of the population. In addition, Jordan University Hospital (JUH) and King Abdullah University Hospital (KAUH) provide health care services for the Universities employees and dependents and also serve as referral centers. The remaining is covered by insurance companies associated with banks, professional syndicates, universities or private companies. Being successful in dealing with communicable diseases and with its economic manifestations, the burden of disease in Jordan has shifted toward non-communicable diseases (NCD). This is reflected in the Jordan national health priorities list: (Cardiovascular diseases, Cancer, diabetes, Osteoporosis and Neuropsychiatric disorders) (4) .
Although patients seeking treatment in the public sector have to pay very small charges of the prescribed drugs as copayment, some drugs are routinely out-ofstock in the public sector with no substitutes available, forcing the patients to pay for the drugs out-of-pocket from retail pharmacies in the private sector. The latter provides primary, secondary, tertiary & quaternary services through a network of private clinics, polyclinics, and hospitals. Patients seeking treatment in the private sector purchase their drugs directly from the private health center, or its retail pharmacies (5) .
Jordan has a fairly well developed high quality local pharmaceutical manufacturing sector. Currently, there are 16 companies which manufacture mostly generics or branded generics. The local manufacturers engage in contract manufacturing for global pharmaceutical companies, currently contributing to less than 5% of the overall pharmaceutical sector revenue. Given the relatively small size of the Jordanian market compared to minimum efficient plant size in pharmaceutical production, most of these companies are export-oriented, with more than70% of their production sold in more than 65 countries worldwide. As one of the biggest producers of pharmaceutical products in the Middle East, Jordan has a positive trade balance in pharmaceuticals (6) . Despite of this, it mostly depends on Europe for patented drugs.
In order to market a new drug in Jordan, it has to be approved by Jordan Food & Drug Administration (JFDA). Originator drugs applicant should submit toxicological, pharmacological and clinical data about this new drug, whereas generic drug companies can make abridged applications to get market approval for their products demonstrating that their product is bioequivalent to the original drug. Generic applicant does not need to repeat the clinical safety and efficacy trials performed by the originator company (7) . In many countries, health authorities don't allow the use of originator's data as a reference by generic companies for a period (usually 6 -10 years) after the original product gets approval (8) . The latter is called data exclusivity (not a patent) which refers to a practice whereby, for a fixed period of time, drug regulatory authorities do not allow the registration files of an originator to be used for application for a therapeutically equivalent generic version of that medicine. In fact, the strongest impact may be felt in a country where there is no patent for a medicine (if data exclusivity is granted) this will provide a monopoly for a set period (e.g. five years). Jordan's pharmaceutical industry has grown rapidly during the 1990s, partly as a result of a "copycat" strategy that emphasized simple adaptations of global pharmaceutical innovations over local innovation. Jordan's accession to the World Trade Organization (WTO) in 2000 put an end to this practice and raised the pressure on Jordan's manufacturers to reinvent their strategies. Jordan joined the WTO as the 136th member in 2000, and then continued a decade-long reform process of upgrading its intellectual property laws under the U.S./Jordan Free Trade Agreement (USJFTA) in 2001 (9) .
Trade Related Intellectual Property Rights (TRIPS) brings in uniformity in the standards of intellectual property rights among the member countries of the WTO irrespective of their developmental status. While this is expected to result in free flow of technology and investment among the member countries, yet the extent to which the benefits will accrue depend on the domestic industry and the developmental status of the country that is undertaking the reform measures. The claimed benefits of data exclusivity relate, to a great extent, to the additional incentives offered to companies in the long and expensive process of pharmaceutical Research & Development (R&D). Data exclusivity gives companies an incentive to extend the original use of the product (for example, to a wider population, by age or geography, or in new indications for therapeutic use) where, for one reason or another, no patent protection is available. Data exclusivity provides an additional opportunity for originator companies to recoup their investments where marketing approval is given late in the patent life, so that the protection afforded extends beyond patent expiry (10) .
In many developing countries there are numerous medicines that are not patented (even if they are patented in developed countries). In addition, even where there are patent laws, companies may not have considered the market sufficiently valuable to justify the expense and administrative cost of securing patents.
Like most developing countries, Jordan relied heavily on generic medicines, until the country implemented the TRIPS agreement in 2000. Under the terms of its accession to the World Trade Organization WTO in 2000, Jordan was required to introduce TRIPS-plus provisions in its national patent laws in 2004. The latter supposed to improve the ability to develop generic medicine and engage in new innovative research, as well as increasing the presence of and collaboration with multinational drug makers, but indeed TRIPS plus tend to increase the price of new medicines, which keeps them out of reach for all but the elite in developing countries.
Jordan was the first Arab country that signed a free trade agreement FTA with the USA in 2001 allowing for more intellectual property protection in which parallel importation without patent holder's prior consent is forbidden.
The goal of this research was to determine the effect of data exclusivity on the pharmaceutical sector in Jordan after 10 years of implementing TRIPS plus, it is expected that this study could inform decision makers in both public and private sectors while establishing future strategies toward more developed pharmaceutical industry. As being the first of its nature in Jordan; this comparative descriptive study is trying to analyze the effect of data exclusivity on the pharmaceutical sector in Jordan before and after the implementation of data exclusivity.
Methodology
Sales of all pharmaceutical products in Jordan, including all dosage forms, expressed as quantities as well as values were obtained either from JPD or from International Medical Statistics (IMS) quarterly Jordan market reports (2010); the top five selling groups out of the 16 available groups (groups are classified according to The Anatomical therapeutic code ATC-WHO) were selected as they represent 66% of total sales by value in 2010 focusing in non-communicable diseases (NCD) or chronic diseases such as hypertension, coronary heart disease, diabetes mellitus, etc. Two groups were excluded as they are out of the scope of this research i.e. not chronic mostly (anti-infective and Miscellaneous).
The three selected groups (Alimentary & Metabolism, Cardiovascular and Nervous system) included 140 products (Details are available as Tables upon request) . Data collected included: drug name, strength, price, quantities sold in the private or purchased in tenders, number of equivalent generics available for the originator, date of launch for originator & first generic and data exclusivity expiration date for the originator. In order to avoid packaging and strengths variation per each product, if any, an internationally accepted unit of measurement: "Defined Daily Dose" (DDD) was used. WHO defines DDD as the assumed average maintenance dose per day for a drug used for its main indication in adults (11); DDD for each product was obtained.
A. Tenders:
Actual purchased quantities in tenders for the period 2004-2010 were converted to DDD for each dosage form for each product. Cost per DDD was calculated by dividing total sales value for each product in each year by total DDD quantities for the same. Estimated cost difference (savings) were calculated for each product by subtracting cost of DDD for the first generic launched from cost of DDD of its equivalent originator.
B. Private:
Data collection tool spreadsheets were created to record the prices of originators and its equivalent generics for each product.
Prices of originator and its equivalent generic (s) were obtained from IMS Jordan for the year 2010. Price differences between originator and generic were calculated in order to estimate cost saving.
Results
During the analysis of the 140 products that were awarded in Jordan Tenders (2004-2010) 
1-Group 1 (originator to generic):
In order to investigate if there is any difference in cost/DDD when the generic entered the market, the total DDD purchased per each product belongs to the (originator to generic) group and cost per each DDD for the years 2004-2010 were calculated as shown in Table 2 .
In addition,, registration dates for originator and the date of registration & launch for its first equivalent generic (2004-2010) were categorized in Table 3 .
The cost/DDD was decreased once the equivalent generic entered the market; the trend analysis showed a continuous decrease since 2004 till 2010 and presence of equivalent generic reduced the cost/DDD. As shown in Table 3 , three products (valsartan, leviteracitam, celecoxib) from this group were selected for trend analysis in the private market as they were under data exclusivity during 7 years of the study period and the generic entry date was 2009 & 2010 for these products (Table 4) . The pharmacy prices in the Jordanian private sector for the three products (valsartan, leviteracitam & celecoxib) as originator brand and available generics (IMS-2010) are shown in Table 5 . In the private market, only 14 products out of the 19 were available as the others are mainly hospital productsand the products in hospital are not included in IMS Jordan data-. Figure 2 shows sales value in the private market for products in group only originator from 2005-2010.
Figure 2: Sales value in private market for 14 products in only originator
The cumulative sales value for the 14 products (rosuvastatin, pioglitazone, ramipril,, nebivolol, telmisartan, quetiapine, ezetimibe, zolpidem, moxonidine, rivastigmine, eprosartan, atomoxetine, infliximab, nitroprusside) under data exclusivity in group only originator was 17,150,900 JDs in the private market. The latter high expenditure will be much less if generics were available.
3-Group 3: Generic to originator:
This group includes only one drug (clopidogrel) as originator brand was awarded in the tender after the generic was awarded before, the reason for this may be due to clinical guidelines that recommended the use of the originator brand immediately after catheterization for 3 months followed by a generic regardless of the price. The letter increased the cost/ DDD by 141% as the originator was much more expensive than the generic.
Due to a price difference of 37.4 JD in 2010 (originator awarded) over 2009 (generic awarded), the cost to the government increased by extra 179,829 JD in 2010.
On the other hand, in the private sector, Table 6 shows the pharmacy prices after expiration of data exclusivity and generics entered the market in which prices were much less by 56%. 
4-Group 4: Only Generic
Only Generic group was not studied as the equivalent generic for the originator was already available in the market which means that no data exclusivity hinders their presence.
On summary, results of this research found that the total products under data exclusivity were 22 out of the 140 representing 16% of the total studied products in term of unit sales and 9.4% of total sales value which equal to 5,734,673 JD. Table 7 shows the overall trend analysis summary for the studied groups. 
Discussion
Authors would like to acknowledge that although this is a retrospective observational type of study. With the inherited limitations with this design a causal relationship can't be well established.
One important point worth mentioning before starting the discussion; generics were not available although data exclusivity was expired for some years. The latter was attributed to many reasons; sometimes products were not feasible economically i.e. not attractive to be marketed (low sales value), others are available in dosage forms that cannot be produced by local generic companies (e.g. injectable).
Over the years, the TRIPS-plus FTAs have been much criticized for their possible conflict with TRIPS norms and their potential negative impact on access to medicine for developing countries (12) .
Moreover the protections resulted from FTA negatively impacted affordability and availability of medicines in Jordan. It also challenged the claim that stronger IP protection leads to greater foreign direct investment which was not the case in the pharmaceutical industry in Jordan. Besides, there is no evidence to support claims that the FTA has enhanced availability and accessibility of medicines in Jordan. As stricter IP rules led to dramatic increases in the price of key medicines to treat cancer and heart disease, which are the main causes of death in the country. Furthermore, it neither attracted foreign investment, nor improved local manufacturers' R&D capacity or led to more collaboration between national and multinational pharmaceutical companies (13) .
On the other hand, medicines prices have continued to rise in Jordan after IP rules, but Jordan was not able to use TRIPS safeguards to reduce their cost. Also, Jordanian generic companies have not developed any new medicines since the Free Trade Agreement (FTA). While new medicines were frequently unavailable or unaffordable in Jordan (14) .
The research-based pharmaceutical industry claims that data exclusivity provides incentives for companies to generate the necessary data, since without marketing exclusivity, brand-name companies would not want to conduct expensive preclinical tests and clinical trials (15) .
The argument that data exclusivity laws will encourage the introduction of new medicines into the market betrays a misunderstanding of their implications. In fact, there is a possibility that data exclusivity would actually provide incentives to delay the entry of new products for multinational companies would prefer to keep prices high in developed markets by delaying their entry into the developing world at lower prices (16) .
The tension between patent law and public health concerns such as access to medicine has long been an issue of much debate. The requirement of patent protection for pharmaceutical products and various other relevant provisions under the TRIPS agreement signifies this tension as they have created considerable difficulties for developing countries acquiring the medicines needed to address their public health concerns, despite the flexibilities that had been built into the agreement. Hence, the Doha Declaration on the TRIPS agreement and public health has been adopted in 2001 to address this issue, hoping to provide relief to this tension between public health policies and intellectual property rights legislations. Nevertheless, this tension seems to have been further heightened with the proliferation of the FTAs, through which developed countries such as the US and the EU have introduced TRIPS-plus obligations that go beyond the minimum standards set by TRIPS, further exacerbating the tension. Over the years, these TRIPSplus FTAs have been much criticized for their possible conflict with TRIPS norms and their potential negative impact on access to medicines.
Data exclusivity did not affect only Jordan, but also its export market, as the local Jordanian manufacturers will be out of their export markets at least for 7 years;(5 years protection due to data exclusivity, 1 year registration time in Jordan and at least one year registration in export market).
One of the perceived gains of data exclusivity is an increase in foreign direct investment in the pharmaceutical sector and the arrival of newer medicines for Jordanian patients, but in reality this did not happen, most licensing agreements in effect today were signed before 1999, and transfer little know-how to local manufacturers. Furthermore, Egypt, in contrast to Jordan, has no TRIPS-Plus provisions in its IPR law yet still enjoys a significant amount of foreign investment in its pharmaceuticals industry.
Conclusion
This study indicated that data exclusivity for the pharmaceutical products seems likely to generate negative impacts on Jordan in terms of higher drug prices. It is also suggested that data exclusivity, on one hand, would have no relation whatsoever to the rate of R&D and foreign investment, but, on the other hand, is likely to impede the industrial development process of the country. Additional expenditure for medicine with no generic equivalent was resulted from the enforcement of data exclusivity.
